A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation

British Journal of Dermatology

Volumn 150, Issue 6, 2004, Pages 1202-1207

  Sasaki, K ^a   Sugaya, M ^a   Fujita, H ^a   Takeuchi, K ^a   Torii, H ^a   Asahina, A ^a   Tamaki, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anaplastic large cell lymphoma; Anaplastic lymphoma kinase; CD30; Translocation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ADULT; ANAPLASTIC LARGE CELL LYMPHOMA; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IN SITU HYBRIDIZATION; LYMPHOCYTIC INFILTRATION; LYMPHOMA CELL; MEDICAL EXAMINATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN LYMPHOMA; TUMOR VOLUME;

ANTIGENS, CD30; ANTIGENS, CD4; CYTOPLASM; FACIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOPHENOTYPING; KNEE; LEG DERMATOSES; LYMPHOMA, LARGE-CELL; MIDDLE AGED; PROTEIN-TYROSINE KINASES; RECEPTORS, INTERLEUKIN-2; REMISSION, SPONTANEOUS; SKIN NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 3142752566     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05987.x     Document Type: Article

References (29)

1. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-58.
2. Beljaards RC, Meijer CJ, Scheffer E et al. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol 1989; 135: 1169-78.
3. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-71.
4. Drexler HG, Gignac SM, von Wasielewski R et al. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000; 14: 1533-59.
5. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinicopathological findings and outcome. Blood 1999; 93: 2697-706.
6. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-4.
7. Shiota M, Fujimoto J, Semba T et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line. AMS3. Oncogene 1994; 9: 1567-74.
8. Fischer P, Nacheva E, Mason DY et al. A Ki- (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2:5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988, 72: 234-40.
9. Lopategui JR, Sun LH, Chan JK et al. Low frequency association of the t(2;5)(p23:q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. A reverse transcriptase-polymerase chain reaction study. Am J Pathol 1995; 146: 323-8.
10. Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277-9.
11. Shiota M, Nakamura S, Ichinohasama R et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954-60.
12. Beylot-Barry M, Lamant L, Vergier B et al. Detection of t(2:5)(p23:q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol 1996; 149: 483-92.
13. Nakamura S, Shiota M, Nakagawa A et al. Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80 (NPM/ALK) expression. Am J Surg Pathol 1997; 21: 1420-32.
14. Herbst H, Anagnostopoulos J, Heinze B et al. ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease. Blood 1995; 86: 1694-700.
15. Wellmann A, Otsuki T, Vogelbruch M et al. Analysis of the t(2;5)(p23:q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Blood 1995; 86: 2321-8.
16. DeCoteau JF, Butmarc JR, Kinney MC et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87: 3437-41.
17. Wood GS, Hardman DL, Boni R et al. Lack of the t(2:5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood 1996; 88: 1765-70.
18. Herbst H, Sander C, Tronnier M et al. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br J Dermatol 1997; 137: 680-6.
19. Su LD, Schnitzer B, Ross CW et al. The t(2:S)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. J Cutan Pathol 1997; 24: 597-603.
20. Vergier B, Beylot-Barry M, Pulford K et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol 1998; 22: 1192-202.
21. Pulford K, Lamant L, Morris SW et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394-404.
22. Benharroch D, Meguerian-Bedoyan Z, Lamant L et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076-84.
23. Colleoni GW, Bridge JA, Garicochea B et al. ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 2000; 156: 781-9.
24. Ma Z, Cools J, Marynen P et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000; 95: 2144-9.
25. Trinei M, Lanfrancone L, Campo E et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 2000; 60: 793-8.
26. Rosenwald A, Ott G, Pulford K et al. t(1;2)(q21;p23) and t(2;3)(p23:q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood 1999; 94: 362-4.
27. Hernandez L, Pinyol M, Hernandez S et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999; 94: 3265-8.
28. Lamant L, Dastugue N, Pulford K et al. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1:2)(q25:p23) translocation. Blood 1999; 93: 3088-95.
29. Aoki M, Niimi Y, Takezaki S et al. CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis. Br J Dermatol 2001; 145: 123-6.